IP Library Granted Patent US 10,059,929
Granted Patent B2
US 10,059,929 · App. 14/918,212 · Granted Aug 28, 2018

Modified template-independent enzymes for polydeoxynucleotide synthesis

Inventors: J. William Efcavitch (San Carlos, CA); Juliesta E. Sylvester (La Jolla, CA)
Assignee: Molecular Assemblies, Inc.
C12N9/1264C12P19/34C12Y207/07031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,059,929
App. No.
14/918,212
Filed
Oct 20, 2015
Granted
Aug 28, 2018
Kind
B2
Art Unit
1656
USPC
435/91.1
Abstract

The invention includes methods for identifying polymerases, such as modified terminal nucleotidyl transferases (TdT), that are capable of binding nucleotides comprising removable 3′-O-blocking moieties to a nucleic acid initiator, without the use of a template. The invention further includes the identified polymerases, and methods of using the polymerases for de novo synthesis of predetermined oligonucleotide sequences.

Claims (19)

1. A modified terminal deoxynucleotidyl transferase (TdT) comprising a mutation in the TGSR motif and capable of adding a nucleotide analog comprising a removable 3′-O-blocking moiety to the 3′-OH of a nucleic acid initiator in the absence of a nucleic acid template.

2. The modified TdT of claim 1 , wherein the modified TdT comprises an N-terminus t-138 bovine TdT and a protein tag sequence fused to the N-terminus.

3. The modified TdT of claim 1 , wherein the modified TdT comprises an N-terminus t-151 bovine TdT and a protein tag sequence fused to the N-terminus.

4. The modified TdT of claim 1 , wherein the modified TdT comprises an N-terminus t-160 bovine TdT and a protein tag sequence fused to the N-terminus.

5. The modified TdT of claim 1 , wherein the modified TdT exhibits an increased rate of incorporation of modified nucleotides, compared to native TdT.

6. The modified TdT of claim 1 , wherein the modified TdT is capable of adding adenine, cytosine, guanine, and thymine deoxyribonucleotides modified with a removable 3′-O-blocking moiety.

7. The modified TdT of claim 6 , wherein said nucleotides are 2′-deoxyribonucleotides.

8. The modified TdT of claim 1 , wherein the modified TdT is capable of adding adenine, cytosine, guanine, and uracil ribonucleotides modified with a removable 3′-O-blocking moiety.

9. The modified TdT of claim 1 , wherein said removable 3′-O-blocking moiety comprises a 3′-O-azidomethyl group.

10. The modified TdT of claim 1 , wherein said removable 3′-O-blocking moiety comprises a 3′-O-amino group.

11. The modified TdT of claim 1 , wherein said removable 3′-O-blocking moiety comprises a 3′-O-allyl group.

12. The modified TdT of claim 1 , wherein said removable 3′-O-blocking moiety is selected from the group consisting of O-phenoxyacetyl; O-methoxyacetyl; O-acetyl; O-(p-toluene)sulfonate; O-phosphate; O-nitrate; O-[4-methoxy]-tetrahydrothiopyranyl; O-tetrahydrothiopyranyl; O-[5-methyl]-tetrahydrofuranyl; O-[2-methyl,4-methoxy]-tetrahydropyranyl; O-[5-methyl]-tetrahydropyranyl; and O-tetrahydrothiofuranyl.

13. The modified TdT of claim 1 , wherein the modified TdT is capable of incorporating a 3′-O-blocked nucleotide 5′-triphosphate, and said removable blocking moiety comprises a group selected from esters, ethers, carbonitriles, phosphates, carbonates, carbamates, hydroxylamine, borates, nitrates, sugars, phosphoramide, phosphoramidates, phenylsulfenates, sulfates, sulfones and amino acids.

14. The modified TdT of claim 1 , wherein the modified TdT is capable of incorporating modified nucleotides at a reaction temperature of about 30° C.

15. The modified TdT of claim 1 , wherein the modified TdT is capable of incorporating modified nucleotides at a reaction temperature from 30° C. to 80° C.

16. The modified TdT of claim 1 , wherein the modified TdT is capable of incorporating modified nucleotides at a concentration of 1000 μM or less.

17. The modified TdT of claim 16 , wherein the modified TdT is capable of incorporating modified nucleotides at a concentration of 100 μM or less.

18. The modified TdT of claim 1 , wherein the modified TdT is expressed by an organism having a genome comprising a nucleic acid sequence being at least 90% identical to SEQ ID NOS. 2, 4, 6, or 8.

19. The modified TdT of claim 1 , wherein the TGSR motif comprises a mutation selected from G, A, V, L, I, M, F, W, P, S, T, C, Y, N, Q, D, E, K, R, or H.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2016
From: EFCAVITCH, J. WILLIAM; SYLVESTER, JULIESTA E.
To: MOLECULAR ASSEMBLIES, INC.
Reel/Frame 037550/0357 →
Continuity (2)
Provisional Application 62065976 · Oct 20, 2014
Related Publication 20160108382A1 · Apr 21, 2016
Cited By (9)
US 12,209,266 US 12,215,121 US 12,226,746 US 12,281,134 US 12,286,652 US 12,344,876 US 12,415,171 US 12,565,641 US 12,624,351